These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9915036)

  • 1. Control of hepatitis B in the United Kingdom.
    Ramsay M; Gay N; Balogun K; Collins M
    Vaccine; 1998 Nov; 16 Suppl():S52-5. PubMed ID: 9915036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.
    Mele A; Tosti ME; Mariano A; Pizzuti R; Ferro A; Borrini B; Zotti C; Lopalco P; Curtale F; Balocchini E; Spada E;
    Clin Infect Dis; 2008 Mar; 46(6):868-75. PubMed ID: 18269332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of hepatitis B infection in Finland: Implications for immunisation policy.
    Karvonen T; Auranen K; Kuusi M; Leino T
    Vaccine; 2017 Jan; 35(3):412-418. PubMed ID: 28003042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hepatitis B virus infection on women and children.
    Shapiro CN; Margolis HS
    Infect Dis Clin North Am; 1992 Mar; 6(1):75-96. PubMed ID: 1533649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The United Kingdom's hepatitis B immunisation strategy--where now?
    Goldberg D; McMenamin J
    Commun Dis Public Health; 1998 Jun; 1(2):79-83. PubMed ID: 9644118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies.
    Edmunds WJ
    Commun Dis Public Health; 1998 Dec; 1(4):221-8. PubMed ID: 9854877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
    Goldstein ST; Zhou F; Hadler SC; Bell BP; Mast EE; Margolis HS
    Int J Epidemiol; 2005 Dec; 34(6):1329-39. PubMed ID: 16249217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.
    Siddiqui MR; Gay N; Edmunds WJ; Ramsay M
    Vaccine; 2011 Jan; 29(3):466-75. PubMed ID: 21073988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for acute viral hepatitis--United States, 2006.
    Wasley A; Grytdal S; Gallagher K;
    MMWR Surveill Summ; 2008 Mar; 57(2):1-24. PubMed ID: 18354374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy.
    Hahné S; Ramsay M; Balogun K; Edmunds WJ; Mortimer P
    J Clin Virol; 2004 Apr; 29(4):211-20. PubMed ID: 15018847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data--United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Apr; 60(13):410-3. PubMed ID: 21471948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in china.
    Zhao S; Xu Z; Lu Y
    Int J Epidemiol; 2000 Aug; 29(4):744-52. PubMed ID: 10922354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B infection control in Colombian Amazon after 15 years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence.
    Garcia D; Porras A; Rico Mendoza A; Alvis N; Navas MC; De La Hoz F; De Neira M; Osorio E; Valderrama JF
    Vaccine; 2018 May; 36(19):2721-2726. PubMed ID: 29609968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B: evolving epidemiology and implications for control.
    Margolis HS; Alter MJ; Hadler SC
    Semin Liver Dis; 1991 May; 11(2):84-92. PubMed ID: 1832236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes.
    Williams JR; Nokes DJ; Medley GF; Anderson RM
    Epidemiol Infect; 1996 Feb; 116(1):71-89. PubMed ID: 8626006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in the hepatitis B related burden of disease--measuring the success of universal immunisation programs.
    Williams A
    Commun Dis Intell Q Rep; 2002; 26(3):458-60. PubMed ID: 12416714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK).
    Iwarson S
    Vaccine; 1998 Nov; 16 Suppl():S63-4. PubMed ID: 9915040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.